"CMF regimen"[nm] - Search Results

Year	Number of Results
1981	2
1982	13
1983	32
1984	46
1985	57
1986	51
1987	30
1988	24
1989	41
1990	25
1991	31
1992	18
1993	29
1994	16
1995	15
1996	23
1997	24
1998	26
1999	19
2000	28
2001	33
2002	29
2003	36
2004	23
2005	35
2006	35
2007	35
2008	34
2009	22
2010	16
2011	19
2012	17
2013	7
2014	7
2015	7
2016	2
2017	2
2020	1
2024	0

1

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.

Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E; GEICAM Group (Spanish Breast Cancer Research Group), Spain. Martin M, et al. Ann Oncol. 2003 Jun;14(6):833-42. doi: 10.1093/annonc/mdg260. Ann Oncol. 2003. PMID: 12796019 Free article. Review.

2

CMF revisited in the 21st century.

Munzone E, Curigliano G, Burstein HJ, Winer EP, Goldhirsch A. Munzone E, et al. Ann Oncol. 2012 Feb;23(2):305-11. doi: 10.1093/annonc/mdr309. Epub 2011 Jun 29. Ann Oncol. 2012. PMID: 21715566 Free article. Review.

3

Treating the relapsed patient.

Chlebowski RT. Chlebowski RT. Cancer Treat Res. 1992;60:239-53. doi: 10.1007/978-1-4615-3496-9_11. Cancer Treat Res. 1992. PMID: 1355989 Review. No abstract available.

4

Chemotherapy for breast cancer brain metastases.

Fenner MH, Possinger K. Fenner MH, et al. Onkologie. 2002 Oct;25(5):474-9. doi: 10.1159/000067443. Onkologie. 2002. PMID: 12415203 Review.

5

Adjuvant treatment in node-negative, postmenopausal breast cancer.

Hutchins LF, Arick CL. Hutchins LF, et al. Cancer Invest. 2001;19(7):706-22. doi: 10.1081/cnv-100106146. Cancer Invest. 2001. PMID: 11577812 Review. No abstract available.

6

Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group.

Goldhirsch A, Coates AS, Colleoni M, Castiglione-Gertsch M, Gelber RD. Goldhirsch A, et al. J Clin Oncol. 1998 Apr;16(4):1358-62. doi: 10.1200/JCO.1998.16.4.1358. J Clin Oncol. 1998. PMID: 9552037 Review.

7

Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen).

Locatelli M, Colleoni M, Noberasco C, Nolé F, Orlando L, Munzone E, Peruzzotti G, Goldhirsch A. Locatelli M, et al. Ann Oncol. 1999 Nov;10(11):1394-5. doi: 10.1023/a:1008356726147. Ann Oncol. 1999. PMID: 10631475 Free article. No abstract available.

8

Anthracycline vs nonanthracycline adjuvant therapy for breast cancer.

Tack DK, Palmieri FM, Perez EA. Tack DK, et al. Oncology (Williston Park). 2004 Oct;18(11):1367-76; discussion 1378, 1381. Oncology (Williston Park). 2004. PMID: 15609467 Free article. Review.

9

Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.

Wang S, Shi Y, Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X. Wang S, et al. Med Oncol. 2012 Jun;29(2):547-53. doi: 10.1007/s12032-011-9964-2. Epub 2011 Apr 29. Med Oncol. 2012. PMID: 21528408

10

[Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].

Nagykálnai T. Nagykálnai T. Magy Onkol. 2002;46(4):307-13. Epub 2003 Feb 1. Magy Onkol. 2002. PMID: 12563352 Free article. Review. Hungarian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

879 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

879 results

Results by year